Whole genome analysis on the genetic backgrounds associated with the secondary failure to etanercept in patients with rheumatoid arthritis

References

• Takeuchi T, Tatsuki Y, Nogami Y, Ishiguro N, Tanaka Y, Yamanaka H, et al. Postmarketing surveillance of the safety profile of infliximab in 5000 Japanese patients with rheumatoid arthritis. Ann Rheum Dis. 2008;67:189–94.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigai M, Inokuma S, Ishiguro N, Ryu J, Takeuchi T, et al. Postmarketing surveillance of safety and effectiveness of etanercept in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2011;21:343–51.
   PubMed Web of Science ®Google Scholar
• Koike T, Harigayi M, Ishiguro N, Inokuma S, Takei S, Takeuchi T, et al. Safety and effectiveness of adalimumab in Japanese rheumatoid arthritis patients: postmarketing surveillance report of the first 3,000 patients. Mod Rheumatol. 2012;22:498–508.
   PubMed Web of Science ®Google Scholar
• Nishimoto N, Hashimoto J, Miyasaka N, Yamamoto K, Kawai S, Takeuchi T, et al. Study of active controlled monotherapy used for rheumatoid arthritis, an IL-6 inhibitor (SAMURAI): evidence of clinical and radiographic benefit from an X-ray reader-blinded randomized controlled trial of tocilizumab. Ann Rheum Dis. 2007;66:1162–7.
   PubMed Web of Science ®Google Scholar
• Tanaka Y, Harigai M, Takeuchi T, Yamanaka H, Ishiguro N, Yamamoto K, et al. Golimumab in combination with methotrexate in Japanese patients with active rheumatoid arthritis: results of the GO-FORTH study. Ann Rheum Dis. 2012;71:817–24.
   PubMed Web of Science ®Google Scholar
• Yamamoto K, Takeuchi T, Yamanaka H, Ishiguro N, Tanaka Y, Eguchi K, et al. Efficacy and safety of certolizumab pegol plus methotrexate in Japanese rheumatoid arthritis patients with an inadequate response to methotrexate: the J-RAPID randomized, placebo-controlled trial. Mod Rheumatol. 2014;24:715–24.
   PubMed Web of Science ®Google Scholar
• Takeuchi T, Matsubara T, Urata Y, Suematsu E, Ohta S, Honjo S, et al. Phase III, multicenter, open-label, long-term study of the safety of abatacept in Japanese patients with rheumatoid arthritis and an inadequate response to conventional or biologic disease-modifying antirheumatic drugs. Mod Rheumatol. 2014;24:744–53.
   PubMed Web of Science ®Google Scholar
• Finckh A, Simard JF, Gabay C, Guerne PA, SCQM physicians. Evidence for differential acquired drug resistance to anti-tumour necrosis factor agents in rheumatoid arthritis. Ann Rheum Dis. 2006;65:746–52.
   PubMed Web of Science ®Google Scholar
• Saeki Y, Matsui T, Saisho K, Tohma S. Current treatments of rheumatoid arthritis: from the ‘NinJa’ registry. Expert Rev Clin Immunol. 2012;8:455–65.
   PubMed Web of Science ®Google Scholar
• Funahashi K, Yamashita S, Miura T, Hagiwara T, Nakamura T, Okuda K, et al. The reason of stopping biologics and patients outcome [abstract]. Jpn Clin Rheumatol. 2010; P-2-138.
   Google Scholar
• Bandrés Ciga S, Salvatierra J, López-Sidro M, García-Sánchez A, Durán R, Vives F, Raya-Álvarez E. An examination of the mechanisms involved in secondary clinical failure to adalimumab or etanercept in inflammatory arthropathies. J Clin Rheumatol. 2015;21:115–9.
   PubMed Web of Science ®Google Scholar
• Machiela MJ, Chanock SJ. LDlink: a web-based application for exploring population-specific haplotype structure and linking correlated alleles of possible functional variants. Bioinformatics. 2015;31:3555–7.
   PubMed Web of Science ®Google Scholar
• Purcell S, Neale B, Todd-Brown K, Thomas L, Ferreira MA, Bender D, et al. PLINK: a toolset for whole-genome association and population-based linkage analysis. Am J Hum Genet. 2007;81:599–75.
   Web of Science ®Google Scholar
• Matsubara T, Koyano S, Funahashi K, Middleton JE, Miura T, Okuda K, et al. Validation of algorithms using genome-wide SNP analysis for prediction of remission or low disease activity for infliximab – or etanercept-treated RA patients. Arthritis Rheum. 2012;64(Suppl.):S564; Abstract 1314.
   Google Scholar
• Honne K, Hallgrímsdóttir I, Wu C, Sebro R, Jewell N, Sakurai T, et al. A longitudinal genome-wide association study of anti-tumor necrosis factor response among Japanese patients with rheumatoid arthritis. Arthritis Res Ther. 2016;18(12):1–10.
   PubMed Web of Science ®Google Scholar
• Cui J, Stahl E, Saevarsdottri S, Miceli C, Diogo D, Trynka G, et al. Genome-wide association study and gene expression analysis identifies CD84 as a predictor of response to etanercept therapy in rheumatoid arthritis. PLoS Genet. 2013;9:1–11.
   Web of Science ®Google Scholar
• Plant D, Bowes J, Potter C, Kimme C, Hyrich KL, Morgan AW, et al. Genome-wide association study of genetics predictors of anti-tumor factor treatment efficacy in rheumatoid arthritis identifies associations with polymorphisms at seven loci. Arthritis Rheum. 2011;63:645–53.
   PubMed Web of Science ®Google Scholar
• Julià A, Fernandez-Nebro A, Blanco F, Ortiz A, Cañete JD, Maymó J, et al. A genome-wide association study identifies a new locus associated with the response to anti-TNF therapy in rheumatoid arthritis. Pharmacogenomics J. 2016;16:147–50.
   PubMed Web of Science ®Google Scholar
• Okada Y, Wu D, Trynka G, Raj T, Terao C, Ikari K, et al. Genetics of rheumatoid arthritis contributes to biology and drug discovery. Nature. 2014;506:376–81.
   PubMed Web of Science ®Google Scholar
• Hoshino M, Yoshio T, Onishi S, Minota S. Influence of antibodies against infliximab and etanercept on the treatment effectiveness of these agents in Japanese patients with rheumatoid arthritis. Mod Rheumatol. 2012;22:532–40.
   PubMed Web of Science ®Google Scholar
• Barteld GM, Krieckaert CL, Nurmoharmed MT, van Shouwenburg PA, Lems WF, et al. Development of antidrug antibodies against adalimumab and association with disease activity and treatment failure during long-term follow-up. JAMA. 2011;305:1460–8.
   PubMed Web of Science ®Google Scholar
• Jamnitski A, Bartelds GM, Nurmohamed MT, van Schouwenburg PA, van Schaardenburg DV, Stapel SO, et al. The presence or absence of antibodies to infliximab or adalimumab determines the outcome of switching to etanercept. Ann Rheum Dis. 2011;70:284–8.
   PubMed Web of Science ®Google Scholar
• Vincent FB, Morand EF, Murphy K, Mackay F, Mariette X, Marcell C. Antidrug antibodies (ADAb) to tumor necrosis factor (TNF)-specific neutralizing agents in chronic inflammatory disease: a real issue, a clinical perspective. Ann Rheum Dis. 2013;72:165–78.
   PubMed Web of Science ®Google Scholar
• van Shouwenburg A, van de Stadt LA, de Jong RN, van Buren EE, Kruithof S, de Groot ED, et al. Adalimumab elicits a restricted anti-idiotypic antibody response in autoimmune patients resulting in functional neutralization. Ann Rheum Dis. 2013;72:104–9.
   PubMed Web of Science ®Google Scholar
• Klareskog L, Gaubitz M, Rodríguez-Valverde V, Malasise M, Dougados M, Wajdula J, et al. Assessment of long-term safety and efficacy of etanercept in a 5-year extension study in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2011;29:238–47.
   PubMed Web of Science ®Google Scholar
• Dore RK, Mathews S, Schectman J, Surbeck W, Mandel D, Patel A, et al. The immunogenicity, safety, and efficacy of etanercept liquid administered once weekly in patients with rheumatoid arthritis. Clin Exp Rheumatol. 2007;25:40–6.
   PubMed Web of Science ®Google Scholar
• Furst DE, Gaylis N, Bray V, Olech E, Yocum D, Ritter J, et al. Open-label, pilot protocol of patients with rheumatoid arthritis who switch to infliximab after an incomplete response to etanercept: the opposite study. Ann Rheum Dis. 2007;66:893–9.
   PubMed Web of Science ®Google Scholar
• Virkki LM, Valleala H, Takakubo Y, Vuotila J, Relas H, Koumulainen R, et al. Outcomes of switching anti-TNF drugs in rheumatoid arthritis – a study based on observational data from the Finnish Register of Biological Treatment (ROB-FIN). Clin Rheumatol. 2011;30:1447–54.
   PubMed Web of Science ®Google Scholar
• Wakabayashi H, Hasegawa M, Nishioka Y, Minami Y, Nishioka K, Sudo A. Clinical outcome in patients with rheumatoid arthritis switched to tocilizumab after etanercept or infliximab failure. Clin Rheumatol. 2013;32:253–9.
   PubMed Web of Science ®Google Scholar
• Woetzel D, Huber R, Kupfer P, Pohlers D, Pfaff M, Driesch D, et al. Identification of rheumatoid arthritis and osteoarthritis patients by transcriptome-based rule set generation. Arthritis Res Ther. 2014;16:R84.
   PubMed Web of Science ®Google Scholar
• Walter SA, Cutler RE, Jr, Martinez R, Gishizky M, Hill RJ. Stk10, a new member of the polo-like kinase kinase family highly expressed in hematopoietic tissue. J Biol Chem. 2003;278:18221–8.
   PubMed Web of Science ®Google Scholar
• Tao L, Wadsworth S, Mercer J, Mueller C, Lynn K, Siekieraka J, et al. Opposing roles of serine/threonine kinases MEKK1 and LOK in regulating the CD28 responsive element in T-cells. Biochem J. 2002;363:175–82.
   PubMed Web of Science ®Google Scholar
• Schhiff M, Pritchard C, Huffstutter JE, Rodrigues-Valverde V, Durex P, Zhou X, et al. The 6-month safety and efficacy of abatacept in patients with rheumatoid arthritis who underwent a washout after anti-tumor necrosis factor therapy or were directly switched to abatacept: the ARRIVE trial. Ann Rheum Dis. 2009;68:1708–14.
   PubMed Web of Science ®Google Scholar